Featured Content

Nivolumab Monotherapy Provides Long-Term Benefit Advanced Melanoma

Dacarbazine, although once a staple of melanoma therapy, essentially has no current role in the treatment of any type or stage of melanoma.

Gender-Based Differences in Chemotherapy: Efficacy and Safety

Women and men were found to react differently to treatment with chemotherapy, although gender-based survival differences were not observed.

Moving Targets: Off-Label Prescribing of Targeted Therapies

By way of the TAPUR study, researchers are attempting to evaluate the activity of targeted therapies when they are used in an off-label setting.

Encorafenib Plus Binimetinib Offers a New Option for MEK+BRAF Inhibition

In the immunotherapy era, the optimal setting and sequencing of BRAF+MEK inhibition remains unresolved.

The Patient Behind the EHR: Oncologists Only See Half the Picture

Dr Vorobiof discusses the importance patient factors that can be missed via standard data collection methods for patients with cancer.

More Features>>>

Skin Cancer Resources

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs